MA47221A1 - Anticorps monoclonal à pd-l1 - Google Patents
Anticorps monoclonal à pd-l1Info
- Publication number
- MA47221A1 MA47221A1 MA47221A MA47221A MA47221A1 MA 47221 A1 MA47221 A1 MA 47221A1 MA 47221 A MA47221 A MA 47221A MA 47221 A MA47221 A MA 47221A MA 47221 A1 MA47221 A1 MA 47221A1
- Authority
- MA
- Morocco
- Prior art keywords
- monoclonal antibody
- antibodies
- methods
- relates
- dnas
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne le domaine de la biotechnologie et propose des anticorps qui se lient spécifiquement à pd-l1. L'invention concerne des adn qui codent pour lesdits anticorps, qui correspondent aux vecteurs d'expression, et des procédés de production ainsi que des méthodes de traitement utilisant ces anticorps.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017113141A RU2665790C1 (ru) | 2017-04-17 | 2017-04-17 | Моноклональное антитело к pd-l1 |
PCT/RU2018/050039 WO2018194496A2 (fr) | 2017-04-17 | 2018-04-11 | Anticorps monoclonal à pd-l1 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47221A1 true MA47221A1 (fr) | 2020-04-30 |
Family
ID=63459922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA47221A MA47221A1 (fr) | 2017-04-17 | 2018-04-11 | Anticorps monoclonal à pd-l1 |
Country Status (21)
Country | Link |
---|---|
US (1) | US11236167B2 (fr) |
EP (1) | EP3613770A4 (fr) |
JP (2) | JP2020516323A (fr) |
KR (1) | KR102679554B1 (fr) |
CN (1) | CN111247166B (fr) |
AR (1) | AR113223A1 (fr) |
AU (1) | AU2018255132A1 (fr) |
BR (1) | BR112019021781A2 (fr) |
CA (1) | CA3060395A1 (fr) |
CL (1) | CL2019002894A1 (fr) |
CO (1) | CO2019011458A2 (fr) |
EA (1) | EA201992206A1 (fr) |
JO (1) | JOP20190246A1 (fr) |
MA (1) | MA47221A1 (fr) |
NZ (1) | NZ758093A (fr) |
PE (1) | PE20191786A1 (fr) |
PH (1) | PH12019502298A1 (fr) |
RU (1) | RU2665790C1 (fr) |
UY (1) | UY37683A (fr) |
WO (1) | WO2018194496A2 (fr) |
ZA (1) | ZA201907065B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3268392A2 (fr) | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
AU2018278327B2 (en) | 2017-06-01 | 2023-03-16 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies and methods of use thereof |
EA039662B1 (ru) * | 2017-10-03 | 2022-02-24 | Закрытое Акционерное Общество "Биокад" | Антитела, специфичные к cd47 и pd-l1 |
CN109929037B (zh) * | 2019-04-01 | 2023-03-17 | 华博生物医药技术(上海)有限公司 | 针对程序性死亡配体的结合物及其应用 |
RU2753282C2 (ru) | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
WO2022121846A1 (fr) * | 2020-12-08 | 2022-06-16 | 博际生物医药科技(杭州)有限公司 | Anticorps se liant au pd-l1 et son application |
TW202306998A (zh) * | 2021-06-21 | 2023-02-16 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 特異性結合cd47和pd-l1的分離的雙特異性抗體 |
WO2023187460A1 (fr) * | 2022-04-01 | 2023-10-05 | Mabtree Biologics Ag | Anticorps humain ou fragment de liaison à l'antigène de celui-ci spécifique contre pd-l1 pour améliorer la fonction des lymphocytes t |
US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
JP2532858B2 (ja) | 1985-04-01 | 1996-09-11 | セルテツク リミテツド | 形質転換したミエロ―マ細胞系 |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1991000360A1 (fr) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Reactifs bispecifiques pour le traitement du sida |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
KR0149181B1 (ko) | 1990-06-29 | 1998-08-17 | 데이비드 알, 맥지 | 형질전환된 미생물에 의한 멜라닌의 제조방법 |
EP0814159B1 (fr) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Souris transgéniques capables de produire des anticorps hétérologues |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
WO1992020373A1 (fr) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Anticorps d'heteroconjugues pour le traitement des infections a l'hiv |
AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
US5565323A (en) | 1994-03-30 | 1996-10-15 | Mitokor | Cytochrome oxidase mutations aiding diagnosis of sporadic alzheimer's disease |
US5537905A (en) | 1994-09-08 | 1996-07-23 | Zimmer Industries, Inc. | Nicked cutting rule |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
EP1210428B1 (fr) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, recepteur de b7-4, et son utilisation |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
SI1907424T1 (sl) * | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
CN114835812A (zh) * | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
CA2992770A1 (fr) * | 2009-11-24 | 2011-06-03 | Medimmune Limited | Agents de liaison cibles diriges contre b7-h1 |
US20110280877A1 (en) * | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
EA036814B9 (ru) * | 2011-11-28 | 2021-12-27 | Мерк Патент Гмбх | Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение |
CA2872030A1 (fr) * | 2012-05-31 | 2013-12-05 | Sorrento Therapeutics, Inc. | Proteines liant un antigene qui lient pd-l1 |
MX370848B (es) * | 2012-10-04 | 2020-01-08 | Dana Farber Cancer Inst Inc | Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso. |
TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
WO2016022630A1 (fr) | 2014-08-05 | 2016-02-11 | Jiping Zha | Anticorps anti-pd-l1 |
EP4245376A3 (fr) * | 2014-10-14 | 2023-12-13 | Novartis AG | Molécules d'anticorps de pd-l1 et leurs utilisations |
CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
EP3268392A2 (fr) * | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
WO2017020291A1 (fr) * | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Nouveaux anticorps anti-pd-l1 |
-
2017
- 2017-04-17 RU RU2017113141A patent/RU2665790C1/ru active
- 2017-06-16 JO JOP/2019/0246A patent/JOP20190246A1/ar unknown
-
2018
- 2018-04-11 BR BR112019021781A patent/BR112019021781A2/pt unknown
- 2018-04-11 US US16/605,865 patent/US11236167B2/en active Active
- 2018-04-11 KR KR1020197033829A patent/KR102679554B1/ko active IP Right Grant
- 2018-04-11 PE PE2019002020A patent/PE20191786A1/es unknown
- 2018-04-11 CA CA3060395A patent/CA3060395A1/fr active Pending
- 2018-04-11 MA MA47221A patent/MA47221A1/fr unknown
- 2018-04-11 JP JP2020506702A patent/JP2020516323A/ja active Pending
- 2018-04-11 WO PCT/RU2018/050039 patent/WO2018194496A2/fr unknown
- 2018-04-11 AU AU2018255132A patent/AU2018255132A1/en active Pending
- 2018-04-11 CN CN201880040390.1A patent/CN111247166B/zh active Active
- 2018-04-11 EP EP18786945.8A patent/EP3613770A4/fr active Pending
- 2018-04-11 EA EA201992206A patent/EA201992206A1/ru unknown
- 2018-04-11 NZ NZ758093A patent/NZ758093A/en unknown
- 2018-04-16 AR ARP180100958A patent/AR113223A1/es unknown
- 2018-04-17 UY UY0001037683A patent/UY37683A/es unknown
-
2019
- 2019-10-07 PH PH12019502298A patent/PH12019502298A1/en unknown
- 2019-10-10 CL CL2019002894A patent/CL2019002894A1/es unknown
- 2019-10-16 CO CONC2019/0011458A patent/CO2019011458A2/es unknown
- 2019-10-25 ZA ZA2019/07065A patent/ZA201907065B/en unknown
-
2023
- 2023-03-02 JP JP2023031932A patent/JP2023081942A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JOP20190246A1 (ar) | 2019-10-16 |
NZ758093A (en) | 2022-09-30 |
US11236167B2 (en) | 2022-02-01 |
WO2018194496A3 (fr) | 2019-01-10 |
WO2018194496A2 (fr) | 2018-10-25 |
PE20191786A1 (es) | 2019-12-24 |
CA3060395A1 (fr) | 2019-11-18 |
CN111247166A (zh) | 2020-06-05 |
KR20190140979A (ko) | 2019-12-20 |
AU2018255132A2 (en) | 2019-11-07 |
EP3613770A4 (fr) | 2021-01-27 |
US20200369771A1 (en) | 2020-11-26 |
EA201992206A1 (ru) | 2020-02-21 |
CO2019011458A2 (es) | 2020-01-17 |
JP2020516323A (ja) | 2020-06-11 |
BR112019021781A2 (pt) | 2020-05-05 |
AU2018255132A1 (en) | 2019-10-31 |
RU2665790C1 (ru) | 2018-09-04 |
PH12019502298A1 (en) | 2020-07-06 |
ZA201907065B (en) | 2020-09-30 |
JP2023081942A (ja) | 2023-06-13 |
CN111247166B (zh) | 2024-03-26 |
AR113223A1 (es) | 2020-02-19 |
UY37683A (es) | 2018-11-30 |
CL2019002894A1 (es) | 2020-03-13 |
EP3613770A2 (fr) | 2020-02-26 |
KR102679554B1 (ko) | 2024-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
MA49034B1 (fr) | Anticorps anti-lag3 | |
MA49599B1 (fr) | Anticorps spécifiques à cd47 et pd-l1 | |
MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
MA46619B1 (fr) | Anticorps anti-il-33 et leurs utilisations | |
EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
MA42542B1 (fr) | Molécules se liant à pd-1 et méthodes d'utilisation correspondantes | |
MA42622B1 (fr) | Agents de liaison à tigit et leurs utilisations | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
MA40576B1 (fr) | Anticorps et immunoconjugués anti-her2 | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
MA41596A (fr) | Anticorps anti-tau et leurs utilisations | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
MA38161A1 (fr) | Anticorps anti-bmp-6 | |
PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
MX2023011561A (es) | Anticuerpos anti-nectina-4 y usos de los mismos. | |
MA49607A1 (fr) | Anticorps monoclonal pour il-5ra | |
MA43600B2 (fr) | Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire | |
EA202090944A1 (ru) | Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его | |
MA53186A1 (fr) | Anticorps monoclonal qui se lie spécifiquement à cd20 | |
EA201891196A1 (ru) | Cgrp-антитела и их применение | |
EA201992747A1 (ru) | Антитела к fam19a5 и их применение | |
EA202191243A1 (ru) | Активируемые антитела к cd166 и способы их применения | |
EA202090929A1 (ru) | Антитела, активируемые антитела, биспецифические антитела и биспецифические активируемые антитела и способы их применения | |
EA202092981A1 (ru) | Антитела к l1cam и их применение |